Westchester Capital Management (New York)’s DA32 Life Science Tech Acquisition Corp. Class A Common Stock DALS Stock Holding History

Westchester Capital Management (New York)’s Portfolio DALS Stock Details DALS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-280,900	Closed	-$2.88M	–	369
2023 Q2	$2.88M	Hold	280,900	–	–	0.09%	180
2023 Q1	$2.84M	Hold	280,900	–	–	0.09%	219
2022 Q4	$2.78M	Buy	280,900 +115,000	+69%	+$1.13M	0.08%	255
2022 Q3	$1.61M	Hold	165,900	–	–	0.05%	301
2022 Q2	$1.61M	Hold	165,900	–	–	0.04%	259
2022 Q1	$1.62M	Buy	+165,900	New	+$1.6M	0.04%	253

Westchester Capital Management (New York)'s DALS Position: Q3 2023 in Review

Westchester Capital Management (New York) sold out of DA32 Life Science Tech Acquisition Corp. Class A Common Stock (DALS) in Q3 2023, closing a stake of 280,900 shares — an estimated $2.88M sold.

Westchester Capital Management (New York) first reported a position in DALS in Q1 2022 and held it in 6 quarters. The position peaked at $2.88M in Q2 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.

Westchester Capital Management (New York) reported no remaining DA32 Life Science Tech Acquisition Corp. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Westchester Capital Management (New York) sold 280,900 DA32 Life Science Tech Acquisition Corp. Class A Common Stock shares in Q3 2023, an estimated $2.88M.
Westchester Capital Management (New York) first reported a position in DA32 Life Science Tech Acquisition Corp. Class A Common Stock in Q1 2022 and held it in 6 quarters.
Westchester Capital Management (New York)'s DA32 Life Science Tech Acquisition Corp. Class A Common Stock position peaked at $2.88M in Q2 2023.
0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp. Class A Common Stock as of Q3 2023.

Based on Westchester Capital Management (New York)'s 13F filing for Q3 2023, filed 8 Nov 2023.